PRPH – ProPhase Labs Inc
PRPH — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
0.54
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
EPS Last/This Y
EPS This/Next Y
Price
0.09
Target Price
160
Analyst Recom
1
Performance Q
-93.37
Upside
N/A
Beta
-0.54
Ticker: PRPH
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-09 | PRPH | 0.1364 | N/A | N/A | 0 |
| 2026-03-10 | PRPH | 0.1411 | N/A | N/A | 0 |
| 2026-03-11 | PRPH | 0.1494 | N/A | N/A | 0 |
| 2026-03-12 | PRPH | 0.14 | N/A | N/A | 0 |
| 2026-03-13 | PRPH | 0.1489 | N/A | N/A | 0 |
| 2026-03-17 | PRPH | 0.1 | N/A | N/A | 0 |
| 2026-03-18 | PRPH | 0.09 | N/A | N/A | 0 |
| 2026-03-20 | PRPH | 0.0872 | N/A | N/A | 0 |
| 2026-03-25 | PRPH | 0.0839 | N/A | N/A | 0 |
| 2026-03-26 | PRPH | 0.072 | N/A | N/A | 0 |
| 2026-03-27 | PRPH | 0.0775 | N/A | N/A | 0 |
| 2026-03-30 | PRPH | 0.0811 | N/A | N/A | 0 |
| 2026-03-31 | PRPH | 0.1099 | N/A | N/A | 0 |
| 2026-04-01 | PRPH | 0.0958 | N/A | N/A | 0 |
| 2026-04-06 | PRPH | 0.0801 | N/A | N/A | 0 |
| 2026-04-07 | PRPH | 0.09 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-03-09 | PRPH | 0.14 | - | - | - |
| 2026-03-10 | PRPH | 0.14 | - | - | - |
| 2026-03-11 | PRPH | 0.14 | - | - | - |
| 2026-03-12 | PRPH | 0.15 | - | - | - |
| 2026-03-13 | PRPH | 0.15 | - | - | -1.55 |
| 2026-03-17 | PRPH | 0.12 | - | - | -1.55 |
| 2026-03-18 | PRPH | 0.09 | - | - | -1.55 |
| 2026-03-19 | PRPH | 0.09 | - | - | -1.55 |
| 2026-03-20 | PRPH | 0.08 | - | - | -1.55 |
| 2026-03-23 | PRPH | 0.09 | - | - | -1.55 |
| 2026-03-24 | PRPH | 0.09 | - | - | -1.55 |
| 2026-03-25 | PRPH | 0.10 | - | - | -1.55 |
| 2026-03-26 | PRPH | 0.08 | - | - | -1.55 |
| 2026-03-27 | PRPH | 0.07 | - | - | -1.55 |
| 2026-03-30 | PRPH | 0.07 | - | - | -1.55 |
| 2026-03-31 | PRPH | 0.08 | - | - | -1.55 |
| 2026-04-01 | PRPH | 0.09 | - | - | -1.55 |
| 2026-04-02 | PRPH | 0.10 | - | - | -1.55 |
| 2026-04-06 | PRPH | 0.09 | - | - | -1.55 |
| 2026-04-07 | PRPH | 0.09 | - | - | -1.55 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
No data found
Last Quarter Act. EPS
-0.16
Avg. EPS Est. Current Quarter
-0.41
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
Beta
-0.54
Average Sales Estimate Current Quarter
4
Average Sales Estimate Next Quarter
Fair Value
Quality Score
21
Growth Score
30
Sentiment Score
38
Actual DrawDown %
99.9
Max Drawdown 5-Year %
-100
Target Price
160
P/E
Forward P/E
PEG
P/S
P/B
0.22
P/Free Cash Flow
EPS
Average EPS Est. Cur. Y
-1.55
EPS Next Y. (Est.)
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
Return on Equity vs Sector %
-635.3
Return on Equity vs Industry %
-618.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-1.18
EBIT Estimation
No data found for PRPH
ProPhase Labs, Inc.Sector: Healthcare
Industry: Diagnostics & Research
Employees: 96
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart Esophageal Pre-Cancer diagnostics screening test for early detection of esophageal cancer; genomics testing technologies to analyze entire genomes, including the genes and chromosomes in deoxyribonucleic acid; DNA Expand, a platform that allows consumers to upload their DNA data from previous DNA tests obtained from other service providers; and LB-1 and LB-2 for the treatment of cancer, inflammatory diseases or symptoms and memory related syndromes, diseases or symptoms, including dementia and Alzheimer's disease. In addition, the company provides a broad range of COVID-19 related clinical diagnostic and testing services, comprising PCR testing for COVID-19, and Influenza A and B, as well as rapid antigen testing for COVID-19. It offers its genome sequencing products to consumers online with plans to sell in food, drug, and mass retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.
PRPH
Latest News
—
Caricamento notizie per PRPH…
stock quote shares PRPH – ProPhase Labs Inc Stock Price stock today
news today PRPH – ProPhase Labs Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PRPH – ProPhase Labs Inc yahoo finance google finance
stock history PRPH – ProPhase Labs Inc invest stock market
stock prices PRPH premarket after hours
ticker PRPH fair value insiders trading